Genta Incorporated
31
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.1%
5 terminated/withdrawn out of 31 trials
73.7%
-12.8% vs industry average
16%
5 trials in Phase 3/4
21%
3 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (31)
Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Role: collaborator
Phase II Study of Tesetaxel in Metastatic Melanoma
Role: collaborator
Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Role: collaborator
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
Role: collaborator
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Role: lead
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
Role: lead
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
Role: lead
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Role: lead
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
Role: lead
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Role: lead
Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules
Role: lead
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Role: lead
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Role: lead
A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors
Role: lead
Tesetaxel for Previously Treated Patients With Bladder Cancer
Role: lead
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Role: lead
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
Role: lead
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
Role: lead
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Role: lead
Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function
Role: lead